Stay updated on CAR-T for CD33+ AML Clinical Trial
Sign up to get notified when there's something new on the CAR-T for CD33+ AML Clinical Trial page.

Latest updates to the CAR-T for CD33+ AML Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe record describes a Phase 1 study of CD33-CAR-T therapy for relapsed or refractory acute myeloid leukemia. It states that the study was terminated at the principal investigator’s request and is no longer looking for participants.SummaryDifference57%

- Check19 days agoChange DetectedThe site revision shown in the footer changed from v3.7.2 to v3.8.0, while the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedA banner announces NIH website updates and explains that federal agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check33 days agoChange DetectedThe revision number in the footer changed from v3.7.1 to v3.7.2 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study content, replacing the navigation and study details with an error screen. This blocks access to the trial information on the page.SummaryDifference20%

Stay in the know with updates to CAR-T for CD33+ AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CAR-T for CD33+ AML Clinical Trial page.